Financials data is unavailable for this security.
Cash flow in EURView more
In 2023, cash reserves at Neovacs SA fell by 6.20m. Cash Flow from Financing totalled 6.79m or 1,273.56% of revenues. In addition the company used 1.91m for operations while cash used for investing totalled 11.08m.
Cash flow per share | -24.40 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 138.89 |
---|---|
Tangible book value per share | 138.89 |
More ▼
Balance sheet in EURView more
Current ratio | 1.03 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0133 |
---|---|
Total debt/total capital | 0.0131 |
More ▼